Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group
- PMID: 35066089
- DOI: 10.1016/j.jhep.2021.12.041
Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group
Abstract
Background & aims: Autoimmune hepatitis (AIH) has been well characterised and codified through the development of diagnostic criteria. These criteria have been adapted and simplified and are widely used in clinical practice. However, there is a need to update and precisely define the criteria for both treatment response and treatment.
Methods: A systematic review was performed and a modified Delphi consensus process was used to identify and redefine the response criteria in autoimmune hepatitis.
Results: The consensus process initiated by the International Autoimmune Hepatitis Group proposes that the term 'complete biochemical response' defined as 'normalization of serum transaminases and IgG below the upper limit of normal' be adopted to include a time point at 6 months after initiation of treatment. An insufficient response by 6 months was a failure to meet the above definition. Non-response was defined as '<50% decrease of serum transaminases within 4 weeks after initiation of treatment'. Remission is defined as liver histology with a Hepatitis Activity Index <4/18. Intolerance to treatment was agreed to stand for 'any adverse event possibly related to treatment leading to potential drug discontinuation'.
Conclusions: These definitions provide a simple and reproducible framework to define treatment response and non-response, irrespective of the therapeutic intervention. A consensus on endpoints is urgently required to set a global standard for the reporting of study results and to enable inter-study comparisons. Future prospective database studies are needed to validate these endpoints.
Lay summary: Consensus among international experts on response criteria and endpoints in autoimmune hepatitis is lacking. A consensus on endpoints is urgently required to set a global standard for the reporting of study results and to enable the comparison of results between clinical trials. Therefore, the International Autoimmune Hepatitis Group (IAIHG) herein presents a statement on 5 agreed response criteria and endpoints: complete biochemical response, insufficient response, non-response, remission, and intolerance to treatment, which can be used to guide future reporting.
Keywords: autoimmune hepatitis; complete biochemical response; endpoints; insufficient response; intolerance; non-response; remission.
Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Conflict of interest All authors report no potential conflicts that are relevant to the manuscript. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment in
-
2022 International Autoimmune Hepatitis Group non-response criteria in autoimmune hepatitis: A too early endpoint?J Hepatol. 2022 Nov;77(5):1461-1462. doi: 10.1016/j.jhep.2022.06.007. Epub 2022 Jun 16. J Hepatol. 2022. PMID: 35716845 No abstract available.
-
Rapid response predicts complete biochemical response and histological remission in autoimmune hepatitis.J Hepatol. 2022 Nov;77(5):1463-1464. doi: 10.1016/j.jhep.2022.07.012. Epub 2022 Jul 20. J Hepatol. 2022. PMID: 35870704 No abstract available.
-
Reply to: "Correspondence on 'Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group'": Defining endpoints that guide treatment in autoimmune hepatitis.J Hepatol. 2022 Nov;77(5):1464-1466. doi: 10.1016/j.jhep.2022.07.025. Epub 2022 Aug 17. J Hepatol. 2022. PMID: 35985543 No abstract available.
-
2022 International autoimmune hepatitis group non-response criteria in autoimmune hepatitis: Quick vs. slow responders.J Hepatol. 2023 Mar;78(3):e113-e114. doi: 10.1016/j.jhep.2022.09.026. Epub 2022 Oct 13. J Hepatol. 2023. PMID: 36243178 No abstract available.
-
Reply to: "2022 international autoimmune hepatitis group non-response criteria in autoimmune hepatitis: Quick vs. slow responders".J Hepatol. 2023 Mar;78(3):e115. doi: 10.1016/j.jhep.2022.11.031. Epub 2022 Dec 16. J Hepatol. 2023. PMID: 36535600 No abstract available.
Similar articles
-
External validation of the IAIHG autoimmune hepatitis response criteria in a multicentric real-world cohort.JHEP Rep. 2024 Jun 23;6(9):101149. doi: 10.1016/j.jhepr.2024.101149. eCollection 2024 Sep. JHEP Rep. 2024. PMID: 39247177 Free PMC article.
-
Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis.J Hepatol. 2018 Apr;68(4):754-763. doi: 10.1016/j.jhep.2017.11.020. Epub 2017 Nov 24. J Hepatol. 2018. PMID: 29180000
-
Epigenetic considerations and the clinical reevaluation of the overlap syndrome between primary biliary cirrhosis and autoimmune hepatitis.J Autoimmun. 2013 Mar;41:140-5. doi: 10.1016/j.jaut.2012.10.004. Epub 2012 Nov 25. J Autoimmun. 2013. PMID: 23187010
-
[Autoimmune hepatitis: new diagnostic and therapeutic approach].Rev Med Chir Soc Med Nat Iasi. 2004 Jan-Mar;108(1):32-9. Rev Med Chir Soc Med Nat Iasi. 2004. PMID: 15688753 Review. Romanian.
-
Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue.J Hepatol. 2011 Feb;54(2):374-85. doi: 10.1016/j.jhep.2010.09.002. Epub 2010 Sep 18. J Hepatol. 2011. PMID: 21067838 Review.
Cited by
-
Assessment of human Herpes Virus-8 infection in Iranian cirrhotic patients on the waiting list for liver transplantation: A cross-sectional analysis.New Microbes New Infect. 2024 Oct 2;62:101496. doi: 10.1016/j.nmni.2024.101496. eCollection 2024 Dec. New Microbes New Infect. 2024. PMID: 39429733 Free PMC article.
-
Defining characteristics and long-term prognosis of drug-induced autoimmune-like hepatitis: A retrospective cohort study.United European Gastroenterol J. 2024 Feb;12(1):66-75. doi: 10.1002/ueg2.12499. Epub 2023 Dec 2. United European Gastroenterol J. 2024. PMID: 38041550 Free PMC article.
-
Autoimmune hepatitis with confluent necrosis indicates severe liver injury but responds well to standard immunosuppressive therapy.Histol Histopathol. 2024 Jul;39(7):935-945. doi: 10.14670/HH-18-690. Epub 2023 Dec 14. Histol Histopathol. 2024. PMID: 38126225
-
Impact of hepatic steatosis on treatment response of autoimmune hepatitis: A retrospective multicentre analysis.Front Immunol. 2022 Dec 14;13:1040029. doi: 10.3389/fimmu.2022.1040029. eCollection 2022. Front Immunol. 2022. PMID: 36591223 Free PMC article.
-
Inflammasome and pyroptosis in autoimmune liver diseases.Front Immunol. 2023 Mar 8;14:1150879. doi: 10.3389/fimmu.2023.1150879. eCollection 2023. Front Immunol. 2023. PMID: 36969233 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical